Cargando…
ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation
BACKGROUND: Disease-modifying antirheumatic drug (DMARD)-free remission, the sustained absence of synovitis after DMARD cessation, is increasingly achievable, especially in autoantibody-negative rheumatoid arthritis (RA). However, underlying mechanisms are unknown and patient subgroups that achieve...
Autores principales: | Boeters, Debbie M., Burgers, Leonie E., Sasso, Eric H., Huizinga, Tom W. J., van der Helm – van Mil, Annette H. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518725/ https://www.ncbi.nlm.nih.gov/pubmed/31088574 http://dx.doi.org/10.1186/s13075-019-1902-2 |
Ejemplares similares
-
Response to: “Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation” by Masi and Fleischmann
por: Boeters, Debbie M., et al.
Publicado: (2020) -
Correction to: Response to: “Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation” by Masi and Fleischmann
por: Boeters, Debbie M., et al.
Publicado: (2020) -
Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation? Comment on article by Boeters DM et al.
por: Masi, Alfonse T., et al.
Publicado: (2020) -
Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution
por: Verstappen, M., et al.
Publicado: (2022) -
ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation
por: Verstappen, Marloes, et al.
Publicado: (2022)